The first induced pluripotent stem cell company founded in 2014 focused on cardiac cellular therapy. Licensed IP has years of research from one of the nation's largest regenerative research groups consisting of 23 Scientist's focused on the IPS cardiac area since 2009. Our moon-shot approach has had extensive $12 million dollar research validation which continues with our proven cardiac regeneration after heart attack in our human derived cardiomyocytes. All previous cardiac stem cell trials on average have shown under 3% EF improvement versus our recently published 66% EF improvement 90 days after heart attack which continues to be world's leading cause of death.
Our Board includes the world's leading Cardiac Regenerative Scientist's from Stanford, Mayo, etc to Dr. Philippe Menasche, Professor of Thoracic and Cardiovascular Surgery, University of Paris Descartes. Dr. Menasche is currently the world’s first and only clinician to have completed a Phase I cardiomyocyte stem cell clinical trial in Paris, which recently announced promising results and provides a proof of concept for work for our IPS HEART cardiomyocytes. Others include Dr. John Lynn Jefferies, Director Advanced Heart Failure and Cardiomyopathy Programs at the Cincinnati Children's Hospital Medical Center. Dr. Jefferies has recently completed a Phase I study in Duchenne Cardiomyopathy.